Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older

Inclusion/Exclusion Criteria for Antibody Deficient Patients Inclusion Criteria * Adults 60 years of age and older * Diagnosis of common variable immunodeficiency (CVID), Specific Antibody Deficiency (SAD), or X-linked agammaglobulinemia (XLA) * Receiving replacement gammaglobulin * Willing and able to sign consent and follow study schedule * History of varicella or long-term (greater than or equal to 30 years) residence in the USA Exclusion Criteria * Allergy to Zostavax® or any of its components (i.e gelatin, neomycin) * Absolute CD3, CD4, or CD8 lymphopenia as determined by age specific reference ranges * Poor T cell function as indicated by a \< 30 % increase in T cell response to mitogens or antigens as compared to the age matched normal reference range (in CVID) subjects * Evidence of acute systemic illness or infection at within four weeks of screening or enrollment * Prior herpes zoster infection * Previously received herpes zoster vaccination * Malignancy including solid tumors, leukemia, or lymphoma * Presence of autoimmune or other inflammatory disease * Use of immunosuppressive or immunomodulatory medications including chronic corticosteroids. Treatment for \>2weeks of daily steroids will be considered chronic use. * History of bleeding or chronic skin disorders. * Pregnant or breastfeeding females * Immunizations within one month * Persons with HIV or AIDS * Subject unwilling to sign consent or adhere to study schedule * Any condition that in the opinion of t…